Fundacion SEIMC-GESIDA
Quick facts
Marketed products
- AZT+3TC+ABV (Trizivir) · Infectious Disease / Virology
Trizivir is a fixed-dose combination of three nucleoside reverse transcriptase inhibitors (NRTIs) that block HIV reverse transcriptase to prevent viral replication. - Dolutegravir/Lamivudine as a single pill · Infectious Disease / Virology
Dolutegravir inhibits HIV integrase to prevent viral DNA integration into the host genome, while lamivudine inhibits reverse transcriptase to block HIV replication. - DTG/3TC/ABC + ELV/COBI/FTC/TAF · Infectious Disease / Virology
This is a fixed-dose combination of two antiretroviral regimens that inhibit HIV reverse transcriptase and integrase to suppress viral replication. - ELV/COBI/FTC/TAF · Infectious Disease / Virology
This is a fixed-dose combination of four antiretroviral agents that work together to suppress HIV replication through multiple mechanisms: elvitegravir inhibits integrase, cobicistat boosts drug levels, and emtricitabine and tenofovir alafenamide inhibit reverse transcriptase. - Emtricitabine/tenofovir or abacavir/lamivudine · Infectious Disease / Virology
These are nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) that block HIV reverse transcriptase, preventing viral RNA from being converted into DNA and integrated into host cells. - HPV9v · Oncology / Immunology / Infectious Disease
HPV9v is a 9-valent human papillomavirus vaccine that stimulates immune responses against nine HPV types to prevent infection and HPV-related cancers. - Ritonavir boosted Atazanavir + 2 NRTIs · Infectious Disease
Atazanavir inhibits HIV protease to prevent viral replication, while ritonavir boosts its blood levels, and the two NRTIs block reverse transcriptase to further suppress HIV. - Ritonavir boosted Atazanavir + Lamivudine · Infectious Disease / Virology
This combination inhibits HIV protease and reverse transcriptase to block viral replication, with ritonavir boosting atazanavir levels through CYP3A4 inhibition. - Symtuza® (TAF/FTC/DRV/c) · Infectious Disease / Virology
Symtuza is a fixed-dose combination antiretroviral that inhibits HIV reverse transcriptase and protease to prevent viral replication.
Phase 2 pipeline
- Bezlotoxumab Injection [Zinplava] · Infectious Disease
Inhibits Clostridioides difficile toxin
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: